AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: metronidazole, 500mg, bid, for 7 days (day 8-14)
Study NCT04024254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid Tablet
Description: Folic Acid 1 mg by mouth daily
Study NCT03312036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration and adsorption (CPFA)
Description: Patients affected by acute or acute on chronic liver failure are enrolled to undergo CPFA extracorporeal treatments and the standard medical therapy to recover their basal liver function or as a bridge to liver transplantation
Study NCT01983566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 high fat
Description: BI 207127 as a single dose after a high fat breakfast
Study NCT01983566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 with Omeprazole
Description: BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day
Study NCT02830724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: For Phase I, Days -7 and -6:~Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV~For Phase II, Days -7 and -6:~60 mg/kg/day x 2 days IV
Study NCT02830724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: For Phase I, Days -7 to -5:~Dose Level 1: 25 mg/m(2)/day x 3 days IVPB Dose Level 2: 25 mg/m(2)/day x 3 days IVPB Dose Level 3: 25 mg/m(2)/day x 3 days IVPB Dose Level 4: 25 mg/m(2)/day x 3 days IVPB Dose Level 5: 25 mg/m(2)/day x 5 days IVPB Dose Level 6: 25 mg/m(2)/day x 5 days IVPB~For Phase II, Days -7 to -3:~25 mg/m(2)/day x 5 days IVPB
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: levofloxacin 250mg, bid, for 7 days (day 8-14)
Study NCT01983566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127
Description: BI 207127 as a single dose in fasted state
Study NCT01983566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 low fat
Description: BI 207127 as a single dose after a low fat breakfast
Study NCT02830724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
Study NCT02830724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-hCD70 CAR transduced PBL
Description: Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-5 days after the last dose of fludarabine).
Study NCT01319747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
Study NCT01319747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS-PVI
Description: A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: levofloxacin 250mg, bid, for 7 days (day 8-14)
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin ER
Description: clarithromycin 500mg, bid, for 7 days (day 8-14)
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin ER
Description: clarithromycin 500mg, bid, for 7 days (day 8-14)
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg
Description: Nexium (esomeprazole), 40mg, bid, for 10 days
Study NCT02236039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Bronchoscopy with biopsy sampling, brushings and bronchoalveolar lavage (BAL) 24 hours post exposure.
Study NCT02236039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Bronchoscopy with biopsy sampling, brushings and bronchoalveolar lavage (BAL) 24 hours post exposure.
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Nexium (esomeprazole), 40mg, bid, for 10 days
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dibismuth trioxide
Description: Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
Study NCT03032575 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SEARCH010/RV254
Study NCT04462354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blumgart Anastomosis
Description: Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Blumgart anastomosis
Study NCT04462354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatogastric anastomosis.
Description: Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Pancreatogastric anastomosis.
Study NCT04495296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 will be administered by specified doses on specified day
Study NCT00364767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A
Description: Alcohol consumption (32 g/day) for 4 weeks
Study NCT00364767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: B
Description: Water
Study NCT02431611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomarker feedback (phone based smoking cessation counseling)
Description: Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling
Study NCT02431611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition (phone based smoking cessation counseling)
Description: phone-based behavioral smoking cessation counseling
Study NCT02302417 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spirometry
Description: Classification of respiratory diseases by Spirometry will be performed to differentiate subjects between Asthma only, ACOS, and COPD only. Spirometry obtained from measurements in the past 6 months is acceptable for purposes of this study. For subjects without spirometry in the past 6 months, spirometry will be performed to obtain pre- and post-bronchodilator Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and reversibility
Study NCT02302417 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ACOS clinical questionnaire
Description: The 41-question questionnaire includes questions concerning the following: a) response to bronchodilator, b) disease progression, c) variations in symptom, d) atopic history, e) symptom triggers, f) vagal bias, g) burden of disease, h) symptom presentation, i) emotional aspects, and j) age of onset. In addition, two questions will capture patient perception of his/her respiratory disease and the physician's diagnosis
Study NCT03655405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Deprescribing Intervention
Description: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.
Study NCT04495296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered by specified doses on specified day
Study NCT04495296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered by specified doses on specified day
Study NCT04495296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered by specified doses on specified day
Study NCT04495296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered by specified doses on specified day
Study NCT04495296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dibismuth trioxide
Description: Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
Study NCT04495296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered by specified doses on specified day
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: metronidazole, 500mg, tid, for 10 days (day 1-10)
Study NCT01410747 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: oral
Study NCT04587635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PHGG
Description: PHGG
Study NCT04587635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT03467919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Micro Fragmented Adipose Tissue
Description: Harvesting of Micro Fragmented Adipose Tissue with intra-articular injection
Study NCT03467919 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
Study NCT02162277 — intervention group
Intervention type: DEVICE
Intervention: diagnostic osteoporotic kit ( including 7 genes and 4 life styles)
Description: Most osteoporotic patients want to know what kinds of life styles they should take care of. The device will help it.
Study NCT01294774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP203 - 1.2mg
Study NCT01294774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to KRP203 - 1.2 mg
Study NCT03342378 — intervention group
Intervention type: RADIATION
Intervention: Intensity modulated radiotherapy (IMRT)
Description: Intensity modulated radiotherapy (IMRT) will be delivered over 6.5 weeks in 33 daily fractions. Treatments will be initiated on Monday or Tuesday. Missed treatments will be compensated for by delivering an additional BID treatment during the week given at least 6 hours apart OR treating on the Saturday of that week, OR adding to the end of treatment. Gross disease will receive 70 Gy in 2.12 Gy fractions, areas at high-risk for subclinical disease will receive 60 Gy in 1.82 Gy fractions, and areas at low-risk for harboring subclinical disease will receive 56 Gy in 1.70 Gy fractions.
Study NCT03342378 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET-MRI
Description: All imaging data will be acquired using a 3.0T PET-MRI scanner with a standard bore size of 60 cm. Patients will be placed in standard non-ferrous head and neck immobilization devices during PET-MRI to simulate their anticipated positioning during subsequent CT simulation and treatment. A head and neck PET-MRI study will be performed with scan sequences tailored for the site of interest. The PET-MRI exam will take approximately 90 minutes to complete.
Study NCT01946828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIM
Description: Field Induced Mydriasis device
Study NCT01664637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg TZP-102
Description: One oval-shaped, opaque-white, hard gelatin capsule containing active ingredient will be taken orally three times a day for 12 weeks
Study NCT01664637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
Study NCT00218387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 200mg Modafinil
Study NCT00218387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 400mg Modafinil
Study NCT00218387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo
Study NCT05434988 — intervention group
Intervention type: PROCEDURE
Intervention: appendectomy
Description: Open or Laparoscopic appendectomy procedure is typically performed under general anaesthesia. in the laparoscopic approach, the main principle is the triangulation of instrument ports to visualize and expose the appendix clearly. The first trocar (10 mm) for the optical device is introduced peri-umbilically, followed by two 5 mm trocars, one in the right lower quadrant just above the pubis (to grasp the appendix) and the other in the left iliac fossa (for the (right-handed) surgeon's right hand), assuming the appendix is in its normal anatomic position. The locations of the 5 mm trocars can be changed based on the anatomic position of the appendix as determined before to surgery (for example a subhepatic appendix could lead to placing the trocars as for cholecystectomy)
Study NCT04882813 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin
Description: Dapagliflozin dispensing claim is used as the exposure group.
Study NCT04882813 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin
Description: Sitagliptin dispensing claim is used as the reference group.
Study NCT02691923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescein
Study NCT02691923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein + ALA
Study NCT02659423 — intervention group
Intervention type: BEHAVIORAL
Intervention: BIC 1
Description: BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
Study NCT02659423 — intervention group
Intervention type: BEHAVIORAL
Intervention: BIC 2
Description: BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
Study NCT02659423 — intervention group
Intervention type: BEHAVIORAL
Intervention: BIC 3
Description: BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
Study NCT04138901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided subcostal transversus abdominis plane block (TAPB)
Description: At the end of surgery, an anesthesiologist will perform bilateral subcostal TAP block with 0.375% ropivacaine 15ml at each site under ultrasound guidance.
Study NCT04138901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: 0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
Study NCT04138901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
Description: 0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
Study NCT02303795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: metronidazole, 500mg, tid, for 10 days (day 1-10)
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetracycline
Description: tetracycline 500mg, qid, for 10 days
Study NCT03555526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracycline
Description: tetracycline 500mg, qid, for 10 days
Study NCT01502722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of ingestion sugary and sweetened drinks on thirst
Description: The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
Study NCT03756766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RSV point of care testing
Description: Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
Study NCT01208233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03049423
Description: 1 mg of PF-03049423 daily for 90 days
Study NCT01208233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03049423
Description: 3 mg of PF-03049423 daily for 90 days
Study NCT01208233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03049423
Description: 6 mg of PF-03049423 daily for 90 days
Study NCT01208233 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of PF-03049423 daily for 90 days
Study NCT00674141 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone soduim phosphate
Description: nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
Study NCT03281811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid Hydrochloride
Description: Given topically
Study NCT03281811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo PDT
Study NCT03281811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03281811 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT00797615 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active intervention
Description: 12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
Study NCT00797615 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Alternative Intervention
Description: 12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
Study NCT03735394 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonic probe
Description: apply the head of the ultrasonic probe on the keratinized tissue of the most protruded upper and lower central incisor in order to measure tissue thickness.
Study NCT01795508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMTO
Description: Parent Management Training, Oregon
Study NCT01795508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Other kinds of family training
Study NCT03904979 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Writing exercises
Description: Participants will be given journals with writing prompts to be completed throughout their pregnancy.
Study NCT03904979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Writing exercises
Description: Participants will be given journals with writing prompts to be completed throughout their pregnancy.
Study NCT02287415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study NCT02287415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study NCT00315094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiving support interventions (FamTechCare)
Description: One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
Study NCT04368598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated on days 11 to 14 in the case of lack of response by day 10)
Study NCT04368598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Acetylcysteine, po, 400mg tid, for 4 weeks
Study NCT01769157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Study NCT01769157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00459134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ArginMax
Description: Given orally
Study NCT00459134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally